Literature DB >> 15617951

Likelihood ratio and a Bayesian approach were superior to standard noninferiority analysis when the noninferiority margin varied with the control event rate.

Mimi Y Kim1, Xiaonan Xue.   

Abstract

OBJECTIVE: To present and compare three statistical approaches for analyzing a noninferiority trial when the noninferiority margin depends on the control event rate. STUDY DESIGN AND
SETTING: In noninferiority trials with a binary outcome, the noninferiority margin is often defined as a fixed delta, the largest clinically acceptable difference in event rates between treatment groups. An alternative and more flexible approach is to allow delta to vary according to the true event rate in the control group. The appropriate statistical method for evaluating noninferiority with a variable noninferiority margin is not apparent. Three statistical approaches are proposed and compared: an observed event rate (OER) approach based on equating the true control rate to the observed rate, a Bayesian approach, and a likelihood ratio test. RESULTS AND
CONCLUSIONS: Simulations studies indicate that the proportion of trials in which noninferiority was erroneously demonstrated was higher for the OER approach than with the Bayesian and likelihood ratio approaches. In some cases, the Type I error rate exceeded 10% for the OER approach. The OER approach is not recommended for the analysis of noninferiority trials with a variable margin of equivalence. The Bayesian and likelihood ratio methods yielded better operating characteristics.

Mesh:

Year:  2004        PMID: 15617951     DOI: 10.1016/j.jclinepi.2004.05.005

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  1 in total

1.  Non-inferiority test for a continuous variable with a flexible margin in an active controlled trial: an application to the "Stratall ANRS 12110 / ESTHER" trial.

Authors:  Arsene Brunelle Sandie; Nicolas Molinari; Anthony Wanjoya; Charles Kouanfack; Christian Laurent; Jules Brice Tchatchueng-Mbougua
Journal:  Trials       Date:  2022-03-05       Impact factor: 2.279

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.